In CML, CIP2A is also biologically and clinically important [96,118], as high levels correlate not only with increased levels of MYC, but with upregulation of the antiapoptotic protein BCL-XL [97], another important target of PP2A [119]. This evidence concerns the gene CIP2A and chronic myelogenous leukemia, BCR-ABL1 positive.